Herein, our study indicates that simultaneous inhibition of PI3K/AKT/mTOR signaling and exogenous FAs uptake using a combination of PI3K and CD36 inhibitors might reduce cell proliferation synergistically in anti-HER2 resistant breast cancer with PTEN-loss. This evidence concerns the gene ERBB2 and breast cancer.